Guardian Pharmacy Lifts FY26 EBITDA Outlook to $136-138M After 24% Q3 EBITDA Growth
GRDN sits 51% above its 52-week low of $26.34.
Summary
Guardian beat on profitability and raised the full-year outlook. Q3 Adjusted EBITDA rose 24% to $33.9 million and net income nearly doubled to $19.1 million from $9.6 million, lifting Adjusted EBITDA margin to 9.1% from 7.2%. Revenue slipped 2% to $371.1 million, but the company said that reflects IRA-driven pricing cuts and that sales would have been up high single digits without them; residents served grew 7% to about 218,000. Management raised FY26 Adjusted EBITDA guidance to $136-138 million from $129-131 million and revenue to $1.44-1.46 billion from $1.43-1.45 billion. The balance sheet is clean: $119.7 million of cash and no long-term debt drawn, funding the steady stream of tuck-in acquisitions (Wellness Concepts, Nautilus assets, Van's Institutional Pharmacy) and greenfield openings in Lexington, Houston and Huntsville. The 4:30 pm ET call today is the next checkpoint on margin durability and IRA pricing pressure.
At the time of this announcement, GRDN was trading at $39.87 on NYSE in the Trade & Services sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $26.34 to $48.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.